Uso de Omalizumab en cuadro asmático grave

Abstract

Introduction: Within the spectrum of the most prevalent pathologies in pediatric patients we have asthma whose definition has changed over time, asthmatic disease is now understood as a chronic inflammatory pathology of an etiologically multifactorial nature that addresses both inflammatory and non-inflammatory factors. which give progression to it, among these is neutrophilic inflammation, as well as paucigranulocytic inflammation, however the triggering factor, such as the allergic reaction to multiple allergenic agents, is no longer a common factor in the pathology, it can be triggered even without an allergic reaction. Materials and methods: For the development of this work, a bibliographic search of a systemic nature on the use of omalizumab in severe asthma was carried out in various databases such as Pubmed, ProQuest, Medline, Google Scholar, UpToDate and ScienceDirect electronic sites from which all the information was collected. the information without any restriction on the type of study, nor the language of orig in of the different documents consulted, thus being review articles, case reports, meta-analysis, clinical practice guidelines, among others within the last 5 years, to the writing of In this article, the selection was made according to terms of inclusion and exclusion to make effective the use of a single universal language, some terms were used to filter the information, such as severe asthma AND Omalizumab AND clinical management, resulting in the combination of three terms separated by the preposition AND. Objective: To carry out an updated bibliographic review on the use of omalizumab in severe asthma on all the information sent by the bibliography of the various databases within the last 5 years on therapeutic management, biomarkers that indicate the p rogression of treatment. Conclusions: Asthma as a chronic inflammatory pathology addresses inflammatory and non-inflammatory factors of the respiratory tract, triggering bronchial hyperreactivity due to an allergic reaction in the presence of exposure to allergens, although in many cases it is not necessary to cause said allergic reaction. Likewise, the inflammatory cascade can be both eosinophilic and non - eosinophilic in nature, such as neutrophilic or paucigranulocytic, in which its definition is tied to the need to use high doses of inhaled corticosteroids in adjuvant with long-acting β2 adrenergic agonists, having previously ruled out details such as correct inhalation technique, exposure to risk factors, comorbidities, treatment adherence control.